3 125

Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program

Authors
 Alfonsus J.M. van den Eertwegh  ;  Pierre Karakiewicz  ;  Sevil Bavbek  ;  Sun Young Rha  ;  Sergio Bracarda  ;  Amit Bahl  ;  Yen-chuan Ou  ;  Dennis Kim  ;  Ashok Panneerselvam  ;  Oezlem Anak  ;  Viktor Grünwald 
Citation
 Urology, Vol.81(1) : 143-149, 2013 
Journal Title
 Urology 
ISSN
 0090-4295 
Issue Date
2013
Abstract
OBJECTIVE: To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program. METHODS: Patients with metastatic renal cell carcinoma refractory to vascular endothelial growth factor receptor-tyrosine kinase inhibitor received everolimus (10 mg once daily), with dosing interruption or modifications allowed for toxicity. All serious and grade 3/4 adverse events and grade 1/2 adverse events leading to a change in drug administration were reported. Tumor response was evaluated using Response Evaluation Criteria In Solid Tumors. RESULTS: The study stratified 1367 evaluable patients into treatment duration groups of <3 months, ≥3 and <6 months, ≥6 months and <1 year, and ≥1 year. Pneumonia, noninfectious pneumonitis, and hyperglycemia occurred more frequently in patients receiving everolimus for ≥1 year but did not result in treatment discontinuations. First occurrence of adverse events presented early in the treatment course for most patients. Treatment duration of ≥6 months was associated with improved disease control rates. CONCLUSION: Everolimus is well tolerated in patients with metastatic renal cell carcinoma for treatment durations≥1 year and not associated with cumulative toxicity.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/86583
Full Text
http://www.sciencedirect.com/science/article/pii/S0090429512011107
DOI
10.1016/j.urology.2012.09.019
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
라선영(Rha, Sun Young)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse